Clinical evaluation of combined-modality therapy for bone metastasis of non-small-cell lung cancer.
OBJECTIVE
To compare the therapeutic effects of single- and combined-modality therapy on bone metastasis of non-small-cell lung cancer.


METHODS
Seventy patients with bone metastasis of non-small-cell lung cancer were treated with one of the therapeutic modalities of radiotherapy, radioisotope, chemotherapy or medication with Bonefos respectively, while another 71 cases received combined-modality therapy through different combinations of the already listed modalities.


RESULTS
The single modality of radiotherapy, radioisotope, chemotherapy and Bonefos had similar efficacy in treating the bone metastasis cases, which were 55.0%, 56.2%, 42.1% and 53.3% respectively, with a total efficacy rate of 51.4%. Combined-modality therapy proved to be much superior in terms of the total efficacy rate (76.0%, P <0.05), but the blood and the gastrointestinal toxicity was not significantly reduced as compared with that in single-modality group (P >0.05).


CONCLUSIONS
The combined- modality therapy is more effective for treating bone metastasis of non-small-cell lung cancer than single-modality therapy.
Li
Xin-xu
XX
Department of Surgery, Sanshui District Hospital of Traditional Chinese Medicine, Foshan 5281001, China. lxx_xnyy@163.com
Zhou
Tong-Chong
TC
Zhao
Jian
J
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged